Evotec and Eternygen Enter Collaboration to Identify and Develop Novel Metabolic Disease Therapy
May 06 2014 - 12:38AM
Evotec AG (Frankfurt:EVT) (TecDAX) (ISIN:DE0005664809) and
Eternygen GmbH, a privately owned biopharmaceutical company, today
announced a drug discovery collaboration to develop novel small
molecule inhibitors against an Eternygen target to treat metabolic
diseases using Evotec's technology platform and broad expertise in
drug discovery and pre-clinical development. Eternygen is working
on the sodium coupled citrate transporter NaCT, a novel target
which is a key regulator of energy metabolism involved in the
pathogenesis of fatty liver, diabetes and obesity.
Under the terms of the agreement, Evotec will use its
best-in-class drug discovery platform to discover and develop a
suitable clinical candidate.
Marco Janezic, CEO Eternygen GmbH, said:
"Evotec as a world-leading provider for drug discovery and
development services and its deep expertise in the area of
metabolic diseases is the optimal partner for Eternygen as a
project focused company to drive the development process as fast as
possible until proof of concept."
Dr Mario Polywka, Chief Operating Officer of Evotec,
commented: "We are pleased to enter this collaboration
with Eternygen and we are confident that the combination of
Eternygen's and our expertise in metabolic drug discovery and
development will lead to success."
ABOUT NACT
NaCT, also known as PMCT or SLC13A5, is a sodium coupled citrate
transporter which is predominantly expressed in liver cells and the
mammalian homolog of the INDY ("I am not dead yet") gene in
Drosophila. In mouse studies it was shown that NaCT knock out
protects from adiposity and insulin resistance induced by aging and
high-fat diet. Therefore NaCT is an attractive therapeutic target
for the treatment of non-alcoholic fatty liver disease, obesity,
and type 2 diabetes by influencing the mammalian energy
metabolism.
ABOUT ETERNYGEN GMBH
Eternygen is a Berlin based Biotech Company founded in June 2012
focusing on research, development and marketing of NaCT inhibitors
for the treatment of dietary-related metabolic diseases. The
founding team consists of renowned scientists from leading German
universities as well as serial entrepreneurs from the venture and
industry community. Eternygen is basically a virtually company
using a network of senior industry experts and contract research
organizations to drive the projects forward. Eternygen is financed
by VC Fonds Technologie Berlin managed by IBB
Beteiligungsgesellschaft mbH and two renowned family offices. IBB
Beteiligungsgesellschaft mbH is providing venture capital for
Berlin-based technology-oriented companies. For additional
information please go to www.eternygen.com.
ABOUT EVOTEC
AG
Evotec is a drug discovery alliance and development partnership
company focused on rapidly progressing innovative product
approaches with leading pharmaceutical and biotechnology companies.
We operate worldwide providing the highest quality stand-alone and
integrated drug discovery solutions, covering all activities from
target-to-clinic. The Company has established a unique position by
assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer,
Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals,
MedImmune/AstraZeneca, Roche and UCB. In addition, the Company has
existing development partnerships and product candidates both in
clinical and pre-clinical development. These include partnerships
with Boehringer Ingelheim, MedImmune and Andromeda in the field of
diabetes, with Janssen Pharmaceuticals in the field of depression
and with Roche in the field of Alzheimer's disease. For additional
information please go to www.evotec.com.
FORWARD LOOKING STATEMENTS — Information set
forth in this press release contains forward-looking statements,
which involve a number of risks and uncertainties. The
forward-looking statements contained herein represent the judgement
of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to
a variety of risks and uncertainties, many of which are beyond our
control, and which could cause actual results to differ materially
from those contemplated in these forward-looking statements. We
expressly disclaim any obligation or undertaking to release
publicly any updates or revisions to any such statements to reflect
any change in our expectations or any change in events, conditions
or circumstances on which any such statement is based.
CONTACT: For further information, please contact
Gabriele Hansen
VP, Corporate Communications & Investor Relations
+49.(0)40.560 81-255
+49.(0)40.560 81-222 Fax
gabriele.hansen@evotec.com
Evotec AG
Manfred Eigen Campus
Essener Bogen 7
22419 Hamburg (Germany)
For Eternygen contact
Marco Janezic
Managing Director
Grit Zahn
Head of Research
+49 (0) 30 1207 6983 - 0
+49 (0) 30 1207 6983 - 3 Fax
m.janezic@eternygen.com
g.zahn@eternygen.com
Eternygen GmbH
SophienstraSSe 6
Hackesche Hofe, Hof 6, Aufgang 8
10178 Berlin (Germany)
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Eaton Vance Tax Advantag... (NYSE:EVT)
Historical Stock Chart
From Jul 2023 to Jul 2024